Articles tagged with Vaccine Development
Researchers at UCLA have identified rare T cells capable of targeting a protein found in SARS-CoV-2 and other coronaviruses. By adding a fragment of this protein to vaccines, they hope to create a longer-lasting immune response and increase protection against new variants. This breakthrough could lead to more effective COVID-19 vaccines.
The study found that flu vaccination rates are significantly lower among individuals without regular healthcare providers compared to those with a provider. Vaccination rates increased with age and were higher among those with more medical conditions.
The study found that the Moderna vaccine offered a lower risk of documented infection (21% reduced), symptomatic COVID-19 (44% reduced), hospitalization (55% reduced), ICU admission (10% reduced), and death (2% reduced) compared to the Pfizer vaccine. The results suggest that either vaccine is effective, but Moderna may be slightly mor...
Moffitt researchers have developed a HER3-specific dendritic cell cancer vaccine that delays tumor growth and prolongs survival in mouse models. The vaccine targets the HER3 protein, which is involved in the growth and spread of many different cancer types.
Researchers at University at Buffalo successfully freeze-dried a liposome-based liquid vaccine formula, offering a thermostable solution for future COVID-19 vaccines. The freeze-dried product showed stability at elevated temperatures and induced effective antibody responses in mice.
Researchers have discovered that ulvan extracted from marine algae can prevent the infection of cells with the Corona virus. The study suggests that this cheap and accessible natural material may help solve the global spread of the pandemic in developing countries without access to vaccines.
A recent study estimates that COVID-19 vaccination prevented almost 470,000 deaths among people aged 60 years and older across Europe. The authors found that early implementation of vaccination was associated with the largest reduction in expected deaths.
A real-world study of BBV152 found that two doses resulted in 50% effectiveness against symptomatic COVID-19 in hospital workers. The study's findings support the importance of a second dose for maximum protection, but highlight limitations in estimating vaccine effectiveness against severe outcomes.
Researchers developed a novel vaccine using mRNA technology that prompts a quick response to components of tick saliva, limiting infection. The vaccine offers broad-based protection against other tick-borne diseases and can be used in conjunction with traditional vaccines.
Researchers have developed a new strategy to combat the tick-borne Crimean-Congo hemorrhagic fever (CCHF) virus by reconstructing its structure and identifying neutralizing antibodies. The study, published in Science, offers insights for developing therapeutics and vaccines against the virus.
A new mRNA vaccine, CV2CoV, has demonstrated a ten-fold higher antibody response and significantly improved protective efficacy against COVID-19 compared to the original CVnCoV. The second-generation vaccine induced antigen-specific memory B cell responses and T cell responses in non-human primates.
The CDC's four-tiered vaccine prioritization strategy outperformed most approaches in reducing deaths and cases, while some optimizations could improve outcomes. The study found that prioritizing healthcare workers and individuals under 16 was optimal, but strategies focusing on comorbidities were also effective.
A new vaccine combines the part of the 'spike' protein with a combination adjuvant, inducing full protection in aged mice and potentially equivalent to current mRNA vaccines. The formulation is relatively easy to manufacture and may not require extreme cold storage, enabling its use in more settings.
Researchers have discovered a promising new treatment and vaccine for Alzheimer's disease by targeting the toxic form of amyloid beta protein. Both the antibody-based treatment and the protein-based vaccine reduced Alzheimer's symptoms in mouse models, offering hope for potential transformation in patient lives.
Researchers from the University of Copenhagen have discovered that naturally acquired immunity to malaria works differently than immunity following vaccination. The immune system uses natural killer cells to fight the parasite, which is more tailored to the disease than other typical infections.
The BBV152 COVID-19 vaccine demonstrated robust antibody response and induced 77.8% protection against symptomatic COVID-19 in a phase 3 trial. No severe vaccine-related adverse events or deaths were reported among participants.
A gene-silencing therapy harnessing nanoparticles called small extracellular vesicles (sEVs) for drug delivery has protected against Zika virus transmission in pregnant mice to the mouse fetuses. The treatment reduced fetal neurological damage, including virus-induced brain shrinkage.
A new study reveals that memory T helper cells can work with memory B cells to effectively defend the body against chronic viruses. This finding has direct relevance to developing new vaccines for HIV and hepatitis C, as it suggests a more sustained immune response.
An international research team discovered that intestinal bacteria can distribute their metabolic products throughout the body via the bloodstream using membrane vesicles. The study found that these vesicles can overcome the blood-brain barrier and enter brain cells, suggesting a new method for delivering drugs or vaccines.
A study of 780,225 Veterans found that protection against COVID-19 declined by 38.8% from February to October 2021 for all vaccine types, with overall vaccine protection declining from 87.9% to 48.1%. Vaccination remained protective against death in those who became infected during the Delta surge.
A new protein-based vaccine design has been developed that elicits strong immune responses in mice and does not require cold storage. The technology targets antigen-presenting cells directly, potentially filling global vaccination gaps and offering a manufacturing advantage over existing COVID vaccines.
Researchers at Duke University and UNC-Chapel Hill have identified a new antibody that can block infections and minimize symptoms against a broad array of coronaviruses, including SARS-CoV-1 and SARS-CoV-2. The antibody was tested in animal models and found to be effective in protecting mice against developing severe lung symptoms.
A study of 8,889 vaccinated patients and 88,898 unvaccinated patients found the Ad26.COV2.S vaccine to be effective in reducing SARS-CoV-2 infection. The results support mass vaccination efforts globally amid variant spread.
A new report highlights the alarming global impact of Group B streptococcus, which can lead to up to 150,000 infant deaths annually. Maternal vaccination is seen as a cost-effective solution to reduce this toll, with significant health benefits in all regions.
Researchers at Johns Hopkins Medicine found that antibody levels against SARS-CoV-2 stay higher in people who were infected by the virus and then received protection from mRNA vaccine compared to those who only got vaccinated. A longer interval between virus exposure and first vaccine dose may enhance antibody response.
Researchers at University of Queensland successfully protected mice from COVID-19 using a US-developed vaccine candidate delivered via a pocket-sized, pain-free applicator. The vaccine produced strong immune responses and neutralized multiple variants, including UK and South Africa variants.
A new vaccine has shown significant protection against Valley fever in dogs, offering hope for a potential human vaccine. The study found that two doses provided high levels of protection against the fungal disease.
Researchers developed a device that uses light to manipulate and isolate individual viruses, enabling precise diagnosis, treatment, and study of viruses. The device has the potential to aid in vaccine development and research on SARS-CoV-2 virus, allowing for targeted analysis of specific virus mutants.
Researchers discovered that a lower dose of the first shot, followed by a full-dose booster, significantly improved SARS-CoV-2 vaccine potency in mice. This approach, which involves an extended prime-boost interval, may lead to more robust and durable immune responses.
A recent study published in eLife reveals that the shape of the respiratory syncytial virus (RSV) plays a crucial role in determining infection outcomes. Researchers found that RSV viruses change from long, rod-shaped particles to more rounded ones during infection, which affects the activation of complement proteins by the immune system.
Researchers at Georgia Tech and Emory University have developed an innovative method for delivering vaccines, including those for COVID-19, using a handheld electroporator. The device is powered by a BBQ lighter and uses microneedle technology to reduce the complexity and cost of vaccine delivery.
Researchers compared immune responses elicited by three COVID-19 vaccines over an eight-month follow-up period. The mRNA vaccines showed high peak antibody responses that declined sharply, while the single-shot Ad26 vaccine induced lower initial antibody responses but stable levels over time.
A study by Northwestern University scientists has shown that coronavirus vaccines and prior infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines.
Researchers developed a program to target vaccinations using digital contact tracing technology, which can almost halve the number of vaccines required to bring the pandemic under control. The new program prioritizes individuals with the most contacts for vaccinations while keeping personal data private.
A team of researchers developed a new nanomechanical technique to fast-track the detection of COVID-19 variants. The method provides real-time insights into infection immunity and enables direct classification of variant-binding properties.
Researchers in Japan developed a vaccination approach that promotes the production of antibodies neutralizing SARS-CoV-2 and other coronaviruses. The new strategy involves genetically engineering the spike protein receptor-binding domain to shield its head region, boosting antibody production against the core region.
The University of Kansas Chemical Biology of Infectious Disease Center has received a five-year, $11.35 NIH COBRE grant to expand research on next-generation drug therapies for infectious disease. The center will build on previous accomplishments to push forward biological research and foster a collaborative research network.
Researchers at UToledo have developed a protein-based vaccine that promotes a strong immune response, effectively treating rheumatoid arthritis and improving bone quality. The findings suggest long-term benefits following immunization.
Researchers developed an Internet information system, virusMED, to provide a comprehensive picture of viruses' most important regions. The database contains over 800 strains from 75 different families, including SARS-CoV-2, influenza, Ebola, and HIV-1, enabling scientists to respond quickly and effectively against the next pathogen.
Researchers identified five specific mutations prevalent in Delta Plus infections compared to Delta, highlighting the need for expanded antiviral tools. The findings provide clues on how the virus mutates and evade antibodies produced from previous COVID-19 infections or vaccinations.
Researchers developed a mathematical model to study the action of SARS-CoV-2, enabling the examination of individual virus particles and their spikes. This analysis can help fine-tune prevention and treatment by providing insights into viral load, spike distribution, and cell infection potential.
A global collaboration has identified three groups of antibodies resistant to mutations in the SARS-CoV-2 Spike protein, which could target vulnerable sites on the protein. The study provides a framework for selecting durable antibody cocktails for COVID-19 treatment and will guide the development of more effective antibody therapies.
Researchers have developed a microneedle patch that delivers a COVID-19 DNA vaccine into the skin, causing strong immune responses in cells and mice. The patch can be stored at room temperature for over 30 days, making it an important tool for global COVID-19 vaccine distribution.
Patients with cancer show strong immune response to COVID-19 vaccination without increased side effects. A third booster dose may further increase protection.
Researchers at the University of Illinois found that antibodies from people infected with the original COVID-19 strain do not effectively bind to newer variants. This has implications for vaccine efficacy and the design of possible boosters.
Researchers at the University of Alabama at Birmingham found that SARS-CoV-2 viruses grown in successive generations exhibit increased infectivity, binding to heparan sulfate, and reduced virulence. The study suggests that evolved strains may be used as a basis for development of stable live attenuated vaccines.
A two-dose Ebola vaccine regimen has been found to be safe, well-tolerated, and produce a strong immune response in people over 1 year old. The study also supports the use of this regimen for Ebola virus disease prevention in children and adults.
A recent expert review published in The Lancet concludes that COVID-19 vaccine efficacy against severe disease is high, but booster doses for the general population are not necessary. Vaccination remains highly effective against severe disease, including variants like delta and alpha.
A predictive model estimated that cervical cancer may be eliminated in the US by 2030 in low-poverty areas, but not until 2044 in high-poverty areas. Health care disparities are a major contributor to these disparities, including lower vaccination rates and higher prevalence of cancer-causing HPV types.
Researchers at the University of California - San Diego have developed COVID-19 vaccine candidates made from plant viruses and bacteriophages, which can be stored and shipped without refrigeration. These vaccines trigger high production of neutralizing antibodies in mice, offering a potential solution for global distribution efforts.
Researchers are developing a vaccine to prevent oxycodone use disorder, which affects half of those treated with existing medications. The experimental vaccine has shown promise in preclinical studies and is now being tested in a phase 1a/1b clinical trial at Columbia University.
A novel COVID-19 vaccine candidate demonstrates high efficacy in preclinical models by stimulating the immune system and inducing a robust neutralizing antibody response. The vaccine protects against reinfection and provides better protection than natural immunity, making it a potential supplement to existing vaccines.
Researchers at King's College London found that double vaccination significantly reduces the risk of Long COVID, with a 49% lower likelihood of contracting the virus. Fully vaccinated individuals also experience milder symptoms, fewer hospitalizations, and a lower burden of acute symptoms.
The International Vaccine Institute (IVI) has initiated a Phase II/III clinical trial for the Bharat Biotech Chikungunya vaccine candidate BBV87, evaluating its safety and immunogenicity in healthy adults across five countries. The study aims to develop an affordable vaccine with the aim of achieving WHO prequalification.
Researchers at Purdue University and Houston Methodist have developed a novel TB vaccine formulation that enhances T cell responses to combat tuberculosis. The new vaccine uses autophagy-mediated antigen presentation, showing promising results in improving immune response.
Researchers at the University of Maine are developing more effective, safe, and sustainable fish vaccines using nanocellulose to protect Atlantic salmon against lethal pathogens. The goal is to reduce vaccine costs and side effects while increasing effectiveness.
Researchers at Washington University School of Medicine found that COVID-19 vaccination antibodies are effective against the delta variant. The study analyzed antibodies generated by people in response to the Pfizer vaccine and found that 12 out of 13 antibodies recognized both alpha and delta variants, while one antibody failed to rec...
Researchers at Berkeley Lab have made significant breakthroughs in developing a highly effective COVID-19 antibody therapy and an efficient thermoelectric system that can convert waste heat to electricity. The new antibody, S309, has been shown to neutralize all known SARS-CoV-2 strains and may be more difficult for new mutants to escape.
A large-scale population-based study confirms that COVID-19 vaccines far outweigh the risk of Bell's palsy. The study found a small increased risk of Bell's palsy associated with CoronaVac vaccination, but not with BNT162b2.
Researchers developed a protein-based COVID-19 vaccine that mimics the SARS-CoV-2 virus shape, eliciting both antibody and T cell responses. The vaccine, using polymersomes decorated with multiple copies of the receptor binding domain antigen, shows promise for longer-lasting immunity.